African-Specific Molecular Taxonomy of Prostate Cancer Revealed
By LabMedica International staff writers Posted on 06 Sep 2022 |
Prostate cancer is characterized by considerable geo-ethnic disparity. African ancestry is a significant risk factor for the disease, with 2.7-fold higher mortality rates across sub-Saharan Africa than global averages, yet the genetic and non-genetic factors underlying this is not known.
Prostate cancer is characterized by a highly variable natural history and diverse clinical behaviors; it is not surprising that genome profiling has revealed extensive intra- and intratumor heterogeneity and complexity. The identification of oncogenic subtypes and actionable drug targets are moving prostate cancer management a step closer to the promise of precision medicine.
A large team of international scientists led by those at the University of Sydney, Camperdown, Australia) included in a study 183 treatment-naive patients with prostate cancer who were recruited from Australia (n = 53), Brazil (n = 7) and South Africa (n = 123). While matched for pathological grading, prostate-specific antigen levels are notably elevated within the African patients. DNA extracted from fresh tissue and matched blood underwent 2 × 150 bp sequencing on the NovaSeq instrument (Illumina, San Diego, CA, USA). The team performed whole-genome sequencing (WGS) to generate a large cancer genomics resource for sub-Saharan Africa that includes around two million somatic variants.
The scientists reported that findings specific to patients of African ancestry include an elevated tumor mutational burden, increased percentage of genome alteration, a greater number of predicted damaging mutations and a higher total of mutational signatures, and various cancer driver genes. They also describe a molecular taxonomy for prostate cancer differentiated by ancestry and defined as global mutational subtypes, while uncovering different evolutionary trajectories and mutational processes that suggest both common genetic and environmental factors contribute to the disparity between ethnicities. Significant African-ancestry-specific findings included an elevated tumor mutational burden, increased percentage of genome alteration, a greater number of predicted damaging mutations and a higher total of mutational signatures, and the driver genes NCOA2, STK19, DDX11L1, PCAT1 and SETBP1.
The authors concluded that their study suggests that larger genomic datasets of geo-ethnically diverse and ancestrally defined populations in a unified analysis will continue to identify rare and geographically restricted subtypes in prostate cancer and potentially other cancers. They demonstrated that ancestral and geographical attributes of patients could facilitate studies on cancer population genomics, an alternative to cancer personalized genomics, for a better scientific understanding of nature versus nurture. The study was published on August 31, 2022 in the journal Nature.
Related Links:
University of Sydney
Illumina
Latest Molecular Diagnostics News
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer